Zacks.com featured highlights Halozyme Therapeutics, Arista Networks and Citizens Financial Group Halozyme Therapeutics, Arista Networks and Citizens Financial Group have been highlighted in this Screen of The Week article....…
3 Stocks to Keep an Eye on for Earnings Growth in 2023 As 2023 approaches, its prudent to have a look at stocks like Halozyme Therapeutics (HALO), Arista Networks (ANET) & Citizens…
Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Epinephrine autoinjector market to grow at 8.07% Y-O-Y in 2023; Increasing prevalence of allergies will drive growth -Technavio NEW YORK, Dec. 19, 2022 /PRNewswire/ -- Epinephrine autoinjector market insights - Vendors: 15+, including Adamis Pharmaceuticals Corp., ALK Abello…
Halozyme initiated Overweight at Wells Fargo on partnerships, patent moat Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
4 Analysts Have This to Say About Halozyme Therapeutics Latest Ratings for HALO DateFirmActionFromTo Nov 2021Wells FargoMaintainsOverweight Nov 2021JMP SecuritiesMaintainsMarket Outperform Nov 2021SVB LeerinkMaintainsOutperform …
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do…
Should You Buy Halozyme Therapeutics (HALO) Ahead of Earnings? Halozyme Therapeutics (HALO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings…